HZNP News and Press, Horizon Therapeutics Public Limited Company From 01/31/23

Horizon Therapeutics ( NASDAQ: HZNP ) and Amgen ( NASDAQ: AMGN ) confirmed the companies received a "Second Request" from the Federal Trade Commission in regards to the planned almost $28 billion acquisition of the rare-disease focused company. Horizon fell 0.8% in after ...

Horizon Therapeutics ( NASDAQ: HZNP ) ticked down 0.3% on a report that Amgen ( NASDAQ: AMGN ) received a so-called "2nd request" from the Federal Trade Commission in regards to its planned almost $28 billion acquisition. Horizon ( HZNP ) and Amgen ( AMGN ) are sai...

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets. In light of the recently announced agreement to be acquired by Amgen Inc. and applicab...

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The SMID Cap Growth Strategy targets attractively p...

Update 6:55am: Adds Amgen comment. Horizon Pharmaceuticals ( NASDAQ: HZNP ) dropped 1.6% on a report that Sen. Elizabeth Warren (D-MA) told the Federal Trade Commission she has concerns about Amgen's ( NASDAQ: AMGN ) plan to buy Horizon Therapeutics ( HZNP ) and Indi...

Horizon Pharmaceuticals ( NASDAQ: HZNP ) dropped 1.9% on a report that Sen. Elizabeth Warren (D-MA) has concerns about Amgen's ( NASDAQ: AMGN ) plan to buy Horizon Therapeutics ( HZNP ) and Indivior's plan to buy Opiant Pharmaceuticals ( NASDAQ: OPNT ). Opiant fe...

Summary Viridian was one of my top picks in 2022 and it made the 2023 list again. VRDN-001 data continue to impress and Viridian looks well-positioned to disrupt the thyroid eye disease market later this decade. The data point to VRDN-001 being at least faster acting than Tepezza an...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperformed in the fourth quarter, dr...

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Mid Cap Strategy applies quantitative and funda...